Advancements in Midline Catheter Technology by Access Vascular
Access Vascular’s Breakthrough in Catheter Technology
Access Vascular, Inc., involved in innovative vascular access solutions, has recently shared compelling findings regarding its midline catheter technology. These findings were introduced at a prominent annual scientific meeting of the Association for Vascular Access. Through rigorous evaluations, the company demonstrated a marked reduction in complications associated with its HydroMID™ catheter compared to traditional options.
Evaluating Complications with Traditional versus Advanced Catheters
Comparison studies highlighted the significant benefits of the HydroMID catheter, particularly its reduced complication rates. The device exhibited a complication rate of just 5%, which starkly contrasts with the 25% rate seen with conventional chlorhexidine gluconate-coated catheters. Interestingly, the average dwell time for HydroMID was longer at 10.5 days versus 8.9 days, yet it maintained an impressive 95% completion of therapy compared to less than 80% for its counterpart. These outcomes indicate a substantial stride in ensuring patient safety and treatment efficacy.
Study Insights from Healthcare Professionals
Stevie Gore, an RN participating in the study from Benefis Health System, elaborated on the benefits experienced post-switching to HydroMID. The study aimed to address the growing concerns around midline catheter complications, such as pain, swelling, and catheter-related thrombosis. Gore expressed, 'Our patients have reaped the rewards of lower incidents of pain, swelling, and other complications since adopting the HydroMID catheter.'
HydroMID Catheter's Unique Benefits and Technology
The innovative HydroMID catheter is designed using Access Vascular's proprietary MIMIX™ hydrophilic biomaterial technology, which imitates the body's natural chemistry. Research has indicated that the company’s products can reduce complications by as much as sixfold compared to standard catheters. The in vitro studies revealed a remarkable 99.99% reduction in bacterial adhesion, underscoring the significant role this technology plays in improving clinical outcomes.
About Access Vascular: A Closer Look
Founded with the mission to combat primary complications arising from intravenous therapy, Access Vascular focuses on reducing instances of infection and thrombosis that patients commonly face. This commitment to patient care drives the design and manufacture of advanced intravenous catheters from hydrophilic materials aimed to counteract the body's foreign response to traditional devices. Their FDA-cleared products, HydroPICC® and HydroMID®, exemplify excellence in vascular access technology.
Emphasis on Future Developments
Furthermore, as healthcare continues to evolve, Access Vascular remains at the forefront of innovation in vascular access solutions. The potential implications of their findings emphasize the importance of improving patient care while mitigating complications during intravenous therapy. Investing in continued research and development could yield even more effective solutions for health providers and their patients.
Patient Safety: A Top Priority
Access Vascular’s focus on patient safety is paramount, as their advanced technologies aim to provide healthier interactions for patients requiring vascular access. The commitment to lowering failure and complication rates aligns with global healthcare objectives to ensure that patient experiences are safe and effective.
Frequently Asked Questions
What is the HydroMID catheter?
The HydroMID catheter is an advanced vascular access device made from a hydrophilic biomaterial that reduces complications compared to standard catheters.
What were the study findings?
The study found that the HydroMID catheter had a complication rate of 5%, significantly lower than the 25% rate for traditional catheters.
How does Access Vascular ensure safety?
Access Vascular designs its products to mimic the body’s natural chemistry, aiming to reduce foreign body responses and associated complications.
What is MIMIX™ technology?
MIMIX™ technology refers to the proprietary biomaterial developed by Access Vascular, which is engineered to minimize complications during intravenous therapy.
What are the core products offered by Access Vascular?
Access Vascular offers the HydroPICC® and HydroMID® catheters, both designed to enhance patient safety during vascular access procedures.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.